Lupin, Celon Pharma to jointly develop a generic version of Advair Diskus

MUMBAI, India — Pharma Major Lupin and Celon Pharma announced Tuesday that they have entered into a definitive agreement under which the companies will jointly develop a fluticasone/salmeterol dry powder inhaler product which is a generic version of GlaxoSmithKline's Advair Diskus. Lupin will be responsible for commercialization of the product. Celon will supply the product to Lupin for its commercialization in the United States, Canada, Mexico and other key markets. 

 

"This collaboration is an important milestone in Lupin's efforts to evolve its global inhalation pipeline. We are very pleased to partner with Celon given their experience in the development and manufacturing of fluticasone/salmeterol DPI in Europe," said Vinita Gupta, Lupin CEO. "This coupled with Lupin's expertise in inhalation product development and commercialization in the United States and other markets will accelerate the development of generic Advair Diskus for global markets. We look forward to providing access to high quality, affordable fluticasone/salmeterol DPI as part of our strategy to deliver inhaled products to key markets."

 

GlaxoSmithKline's Advair Diskus had global sales of more than $7 billion as of last fiscal, the companies reported.